Pharmaceutical Executive
Washington DC-As part of its continuing investigation into competition and intellectual property rights, the US Federal Trade Commission and the Antitrust Division of the Department of Justice recently kicked off a series of hearings.
Washington DC-As part of its continuing investigation into competition and intellectual property rights, the US Federal Trade Commission and the Antitrust Division of the Department of Justice recently kicked off a series of hearings. Although concerns about innovator-??generic competition are the main focus, the hearings in Washington and on the West Coast aim to explore wider issues about whether a proliferation of over-broad patents threatens to limit competition in several high-tech industries.
FTC chairman Timothy Muris set the stage for the hearings in a speech last November, spelling out the key issues:
At the same time, a committee on intellectual property issues sponsored by the National Academies of Science is examining the relationship between patent protection and technological advance. The panel is investigating the broad economic impact of changes in patent law in recent decades and expects to issue its findings and recommendations in September 2002.
Executives from biotech companies will discuss "real-world" experiences with patents and competition at the last FTC??Justice hearing scheduled for March 19??20. Testimony from academics, lawyers, and researchers may push Congress to revisit the Waxman-Hatch Act to see if its patent provisions encourage or limit generic drug competition.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.